There are only about a dozen or so FDA approved rapid Flu tests in the US at the moment.
So lets say LDX could get roughly 5% of the market then that would still be somewhere around $100 billion USD a year in annual revenue.
Even at a fraction of that it brings in another revenue stream helping with the Lumos bottom line and cash flow.
Rapid Influenza Diagnostic Tests (RIDTs) | CDC
Add to My Watchlist
What is My Watchlist?
